<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9343">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758745</url>
  </required_header>
  <id_info>
    <org_study_id>P-06-03</org_study_id>
    <nct_id>NCT00758745</nct_id>
  </id_info>
  <brief_title>Randomized Contralateral Clinical Trial With Single-piece (SN60WF) vs. Three Piece (MA60AC) AcrySof Intraocular Lenses (IOLs) on Development of Posterior Chamber Opacification (PCO).</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized contralateral clinical trial with single piece (Model SN60WF) vs. three piece
      (Model MA60AC) AcrySof Intraocular Lenses (IOLs) on development of Posterior Chamber
      Opacifiation (PCO).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Posterior Capsule Opacification (PCO)</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Development of PCO using the EPCO Score. The EPCO score incorporates planimetric &amp; grading assessments. The density of the opacification behind the Intraocular Lens (IOL) is graded clinically as follows: 0=No detectable opacification; 1=Minimal detectable opacification; 2=mild detectable opacification; 3=moderate detectable opacification; 4=severe detectable opacification. The individual PCO score is calculated by multiplying the opacification grade by the fraction of capsule area involved behind the IOL optic. The selection process and grading of areas are subjective.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Model SN60WF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation with the AcrySof Model SN60WF Intraocular Lens (IOL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Model MA60AC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation with the AcrySof Model MA60AC Intraocular Lens (IOL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Model SN60WF</intervention_name>
    <description>Implantation with the AcrySof Model SN60WF Single-piece intraocular lens (IOL) following cataract removal.</description>
    <arm_group_label>Model SN60WF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Model MA60AC</intervention_name>
    <description>Implantation with the AcrySof Model MA60AC multi-piece intraocular lens (IOL) following cataract surgery.</description>
    <arm_group_label>Model MA60AC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 50 years

          -  Clear cornea

          -  Pupil mydriasis â‰¥ 7mm

          -  In the bag Intraocular Lens (IOL)

        Exclusion Criteria:

          -  Ocular pathology - uveitis, glaucoma, pseudoexfoliation syndrome (PEX), high myopia

          -  Previously operated eye

          -  Proliferative diabetic retinopathy

          -  Surgical complications - incomplete rhexis, post capsular rupture (PCR), zonular
             dialysis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Contact Alcon Call Center for Study Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <lastchanged_date>August 15, 2014</lastchanged_date>
  <firstreceived_date>September 23, 2008</firstreceived_date>
  <firstreceived_results_date>July 1, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract</keyword>
  <keyword>Patients</keyword>
  <keyword>bilateral</keyword>
  <keyword>age related</keyword>
  <keyword>undergoing</keyword>
  <keyword>phacoemulsification</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Model SN60WF</title>
          <description>Implantation with the AcrySof Model SN60WF Intraocular Lens (IOL)</description>
        </group>
        <group group_id="P2">
          <title>Model MA60AC</title>
          <description>Implantation with the AcrySof Model MA60AC Intraocular Lens (IOL)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Model SN60WF</title>
          <description>Implantation with the AcrySof Model SN60WF Intraocular Lens (IOL)</description>
        </group>
        <group group_id="B2">
          <title>Model MA60AC</title>
          <description>Implantation with the AcrySof Model MA60AC Intraocular Lens (IOL)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="81"/>
                <measurement group_id="B2" value="81"/>
                <measurement group_id="B3" value="162"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="58"/>
                <measurement group_id="B2" value="58"/>
                <measurement group_id="B3" value="116"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="46"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
                <measurement group_id="B2" value="40"/>
                <measurement group_id="B3" value="80"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="41"/>
                <measurement group_id="B2" value="41"/>
                <measurement group_id="B3" value="82"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Posterior Capsule Opacification (PCO)</title>
        <description>Development of PCO using the EPCO Score. The EPCO score incorporates planimetric &amp; grading assessments. The density of the opacification behind the Intraocular Lens (IOL) is graded clinically as follows: 0=No detectable opacification; 1=Minimal detectable opacification; 2=mild detectable opacification; 3=moderate detectable opacification; 4=severe detectable opacification. The individual PCO score is calculated by multiplying the opacification grade by the fraction of capsule area involved behind the IOL optic. The selection process and grading of areas are subjective.</description>
        <time_frame>Up to 3 years</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Model SN60WF</title>
            <description>Implantation with the AcrySof Model SN60WF Intraocular Lens (IOL)</description>
          </group>
          <group group_id="O2">
            <title>Model MA60AC</title>
            <description>Implantation with the AcrySof Model MA60AC Intraocular Lens (IOL)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Posterior Capsule Opacification (PCO)</title>
            <description>Development of PCO using the EPCO Score. The EPCO score incorporates planimetric &amp; grading assessments. The density of the opacification behind the Intraocular Lens (IOL) is graded clinically as follows: 0=No detectable opacification; 1=Minimal detectable opacification; 2=mild detectable opacification; 3=moderate detectable opacification; 4=severe detectable opacification. The individual PCO score is calculated by multiplying the opacification grade by the fraction of capsule area involved behind the IOL optic. The selection process and grading of areas are subjective.</description>
            <units>Units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.18" spread="0.41"/>
                  <measurement group_id="O2" value="0.15" spread="0.44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were not collected for this study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Model SN60WF</title>
          <description>Implantation with the AcrySof Model SN60WF Intraocular Lens (IOL)</description>
        </group>
        <group group_id="E2">
          <title>Model MA60AC</title>
          <description>Implantation with the AcrySof Model MA60AC Intraocular Lens (IOL)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All study data is held confidential and not be disclosed to a 3rd party without written consent from Alcon Laboratories for a period of 3 years.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Research</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>888.451.3937; 817.568.6725</phone>
      <email>medinfo@alconlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
